Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model
Authors:
- Julie Hviid KlaebelJKJulie Hviid Klaebel
- Mia SkjødtMSMia Skjødt
- Josephine Skat-RørdamJSJosephine Skat-Rørdam
- Günaj RakipovskiGRGünaj Rakipovski
- David H. IpsenDIDavid H. Ipsen
- Anne Marie V. Schou-PedersenASAnne Marie V. Schou-Pedersen
- Jens LykkesfeldtJens Lykkesfeldt
- Pernille Tveden-NyborgPTPernille Tveden-Nyborg
Open Access
- 19 November 2019
- Vol. 11 (11) , 2834
Abstract
Despite affecting millions of patients worldwide, no pharmacological treatment has yet proved effective against non-alcoholic steatohepatitis (NASH) induced liver fibrosis. Current guidelines recommend lifestyle modifications including reductions in dietary energy intake. Recently, therapy with atorvastatin and vitamin E (vitE) has been recommended, although clinical studies on the resolution of hepatic fibrosis are inconclusive. Targeting NASH-induced hepatic end-points, this study evaluated the effects of atorvastatin and vitE alone or in combination with a dietary intervention in the guinea pig NASH model. Guinea pigs (n = 72) received 20 weeks of high fat feeding before allocating to four groups: continued HF feeding (HF), HF diet with atorvastatin and vitE (HF+), low-fat diet (LF) and low-fat with atorvastatin and vitE (LF+), for four or eight weeks of intervention. Both LF and LF+ decreased liver weight, cholesterol and plasma dyslipidemia. LF+ further improved hepatic histopathological hallmarks (p < 0.05), liver injury markers aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (p < 0.05) and reduced the expression of target genes of hepatic inflammation and fibrosis (p < 0.05), underlining an increased effect on NASH resolution in this group. Collectively, the data support an overall beneficial effect of diet change, and indicate that atorvastatin and vitE therapy combined with a diet change act synergistically in improving NASH-induced endpoints.Keywords
Funding Information
- Novo Nordisk (#1001110782)
- Lifepharm Centre for in vivo Pharmacology (#1001109652)
This publication has 48 references indexed in Scilit:
- Chronic Vitamin C Deficiency does not Accelerate Oxidative Stress in Ageing Brains of Guinea PigsBasic & Clinical Pharmacology & Toxicology, 2011
- TGF-β in progression of liver diseaseCell and tissue research, 2011
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortalityHepatology, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial designContemporary Clinical Trials, 2009
- Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemiaMetabolism, 2008
- Ascorbate and Dehydroascorbic Acid as Reliable Biomarkers of Oxidative Stress: Analytical Reproducibility and Long-term Stability of Plasma Samples Subjected to Acidic DeproteinizationCancer Epidemiology, Biomarkers & Prevention, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- A fluorometric method for determination of oxidized and reduced glutathione in tissuesAnalytical Biochemistry, 1976